Melanoma & Skin Cancer
Latest News
Advertisement
Latest Videos
Advertisement
More News
Sun exposure to usually-covered skin is yet another risk for skin cancer.
Dr. Axel Hoos medical lead at Bristol-Myers Squibb on Why Melanoma is Amenable to Immunotherapy
In patients with metastatic melanoma, the BRAF inhibitor vemurafenib led to high objective response rates and durable treatment responses.
Oncologists need to prepare for a new era in which rapidly advancing genetic technology will change the way cancer is treated.
Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses the Cabozantinib Trial Design
Dana Monroe from San Francisco Oncology Associates on Yervoy Side Effects and How Oncology Nurses Can Self-Educate
Dr. Axel Hoos from Bristol-Myers Squibb Explains the Future of Immunotherapy and Ipilimumab's role
Abstracts presented at the 2011 ASCO Annual Meeting will have a major impact on both standard-of-care disease management and the future of clinical trials in multiple settings.
Dr. Lynn M. Schuchter from Penn Medicine on the Progression of Melanoma Care over the past 25 years
Dr. Lynn Schuchter from Penn Medicine Discusses Managing Ipilimumab's (Yervoy) Side Effects with the REMS program
Dr. Axel Hoos medical lead from Bristol-Myers Squibb Describes Ipilimumab and Future Immunotherapies
Dr. Tim Turnham the executive director of the melanoma research foundation Describes the organization
Dr. Axel Hoos from Bristol Myers-Squibb on Tools Available to Measure Ipilimumab's Success
Dr. Lynn M. Schuchter from Penn Med on the Next Steps in Melanoma Research
Dr. Lynn Schuchter chief of Hematology Oncology at Penn Medicine Reserves BRAF Testing for Advanced Melanoma
Dr. Schuchter chief of Hematology Oncology at Penn Medicine on Testing for a BRAF Mutation in Melanoma
The FDA recently approved a new drug formulation, mandated label changes for cigarettes and sunscreens, and issued an opinion on breast implants.
Dr. Jeffrey Infante from Sarah Cannon Research Institute on the Next Step in Melanoma Research
Dr. Axel Hoos Medical Lead in Immunology/Oncology at Bristol-Myers Squibb on a Possible Successor Drug to Ipilimumab
Dr. Nicholas Vogelzang from the Comprehensive Cancer Centers of Nevada Describes Cabozantinib's side effects
Vismodegib has demonstrated positive overall response rates in patients with advanced basal cell carcinoma.
Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada on Cabozantinib Clinical Trial Results
Dr. Jedd D. Wolchok From Memorial Sloan-Kettering Cancer Center on Patients That Had to Stop Treatment Early
Dr. Wolchok From Memorial Sloan-Kettering Cancer Center Explains the Future of Ipilimumab
Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes Candidates for Ipilimumab
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
2
VIR-5500 Receives FDA Fast Track Designation in mCRPC
3
China’s NMPA Approves Adjuvant T-DXd for HER2+ Early Breast Cancer With Residual Invasive Disease
4
Individualized Neoantigen Vaccine Elicits Durable T-Cell Responses in Resected HPV– HNSCC
5